



American Professional Agency

LEADERS IN MEDICAL PROFESSIONAL LIABILITY INSURANCE

Are You Protected Against Cyber-Attacks?

Liability Insurance for Psychiatrists

**Ask about a
Cyber
Endorsement**

Scan for a Quote



AmericanProfessional.com

Endorsed By

AMERICAN
PSYCHIATRIC
ASSOCIATION



Asst/Assoc/Prof of Clinical Pediatrics/ Physician Surgeon/Psychiatry

Hiring Department: Pediatrics

Location: Peoria, IL USA

Requisition ID: 1020638

Posting Close Date: 5/23/2024

The University of Illinois College of Medicine at Peoria (UICOMP) seeks physicians for positions at the level of Professor, Associate Professor or Assistant Professor to enhance an important clinical program.

Pediatric Psychiatrist positions require candidates who are BC in Psychiatry and have completed 4 years in residency and 2 years in fellowship training in Pediatric Psychiatry. Candidates with scholarly and research interests are highly desirable, along with experience in teaching medical students and residents.

Position Summary

The Department of Pediatrics, University of Illinois College of Medicine at Peoria is seeking a psychiatrist who has completed a fellowship in Child and Adolescent Psychiatry at the level of Assistant/Associate Professor or Professor.

Duties & Responsibilities

- Responsibilities – Child Psychiatrist
- Participate in undergraduate, graduate and continuing education programs of the Department.
- Provide outpatient diagnostic and management services for patients in the region with general psychiatric and behavioral needs.
- Provide inpatient psychiatric consultation for children and adolescents.
- Organize and conduct research programs in Child Psychiatry.
- Perform other duties of a university faculty member including committee assignments, curriculum development, student counseling, and administration.

Minimum Qualifications

- Eligible for licensure in Illinois
- Board Certified in Psychiatry
- Board Certified/Board Eligible in Child and Adolescent Psychiatry

About University of Illinois College of Medicine, Peoria (UICOMP) Department of Pediatrics and OSF Healthcare Children's Hospital of Illinois:

UICOMP is one of the three regional campuses of the University of Illinois College of Medicine, one of the largest public medical schools in the country. UICOMP's educational programs include 244 medical students and 300 residents/fellows in 21 different post graduate programs. The Department of Pediatrics is one of the largest departments at UICOMP. In collaboration with the OSF HealthCare Children's Hospital of Illinois, the Department has 19 divisions and over 145 faculty members providing general pediatrics and subspecialty services to the pediatric population in Central Illinois.

About Children's Hospital of Illinois

The current research infrastructure within the Department includes office of research, a dedicated biostatistician and internal research funding mechanism to support our faculty. The primary teaching hospital of UICOMP is Children's Hospital of Illinois, a tertiary care facility serving a 37-county region with a population base of over two million. Children's Hospital of Illinois provides comprehensive services to children, including Level IV NICU and a state-designated Pediatric Critical Care Center. Children's Hospital of Illinois is a major medical facility with 136 beds and a 32-bed critical care unit and the only Level 1 trauma center in Illinois outside of Chicago. There are existing resources through UICOMP and Children's Hospital of Illinois for seeding research funding, quality and outcomes focused academic work and innovation in health education.

About Peoria, IL

One of the oldest communities in Illinois with a population of 112,936, Peoria is equal distance from Chicago and St. Louis. Here we have an enviable standard of living, exciting venues within a 15-20 minute drive from our homes, safe streets, quality and quantity shopping, our own symphony, our own ballet, Broadway Theater League, museums, art guilds, first-class medical facilities, the nation's oldest community theater and oldest Santa Claus parade.

Our vibrant riverfront showcases a multitude of festivals and celebrations that light up the summer nights much like our extraordinary Fourth of July Sky Concert fireworks show that draws well over 100,000 annually. Citizens are flocking to live in the refurbished warehouses and lofts on Water Street that produce the perfect lifestyle for a 24/7 city.

We have many global businesses that allow Peoria to play all over the world through their products and services. Peoria has begun to diversify its economy with infotech industries as well. Thus our business community attracts some of the brightest graduates throughout the nation.

For fullest consideration, please submit your application by 3/15/2024 at:
<https://uic.csod.com/ux/ats/careersite/1/home/requisition/6600?c=uiic>

The University of Illinois System is an equal opportunity employer, including but not limited to disability and/or veteran status, and complies with all applicable state and federal employment mandates. Please visit Required Employment Notices and Posters at <https://www.hr.uillinois.edu/cms/one.aspx?portalId=4292&pageId=5705> to view our non-discrimination statement and find additional information about required background checks, sexual harassment/misconduct disclosures, COVID-19 vaccination requirement, and employment eligibility review through E-Verify.

The University of Illinois conducts background checks on all job candidates upon acceptance of a contingent offer of employment. Background checks will be performed in compliance with the Fair Credit Reporting Act.

As an EOE/AA employer, the University of Illinois encourages applications from individuals regardless of an applicant's race, color, religion, sex, gender identity, sexual orientation, national origin, and Veteran or disability status.

The university provides accommodations to applicants and employees. Request an Accommodation at <https://jobs.uic.edu/request-and-accommodation/>

The university provides accommodations to applicants and employees. Request an Accommodation at <https://jobs.uic.edu/request-and-accommodation/>



Call for Nominations

The Institute of Living/Hartford Hospital is pleased to announce that nominations are now being accepted for the 2021 C. Charles Burlingame Award. This award, honoring an outstanding leader in psychiatric education, research or administration, is made in the memory of Dr. Burlingame, psychiatrist-in-chief from 1931 to 1950.

We invite you to nominate a person who has significantly advanced the field of psychiatry. The nomination must include a current curriculum vitae and two letters of support describing the candidate's achievements.

The Institute of Living is a comprehensive behavioral health system for the evaluation and treatment of psychiatric and addiction disorders. We offer a full continuum of services to patients and remain committed to the highest standards of clinical care, research and education.

Past Recipients

1988 Robert Kellner, M.D., Ph.D.	2007 Jerrold F. Rosenbaum, M.D.
1989 William T. Carpenter, Jr., M.D.	2008 K. Ranga Rama Krishnan, M.D.
1990 Dennis P. Cantwell, M.D.	2009 David J. Kupfer, M.D.
1991 George E. Vaillant, M.D.	2010 Professor Sir Michael Rutter
1992 A. John Rush, M.D.	2011 Jeffrey A. Lieberman, M.D.
1993 John C. Nemiah, M.D.	2012 Judith L. Rapoport, M.D.
1994 Maurice J. Martin, M.D.	2013 Nora D. Volkow, M.D.
1995 Otto F. Kernberg, M.D.	2014 Daniel R. Weinberger, M.D.
1996 Charles P. O'Brien, M.D., Ph.D.	2015 David A. Brent, M.D.
1997 Glen Owen Gabbard, M.D.	2016 Steven S. Sharfstein, M.D.
1998 Lissy F. Jarvik, M.D., Ph.D.	2017 Harold Alan Pincus, M.D.
1999 Nancy C. Andreasen, M.D., Ph.D.	2018 Kenneth S. Kendler, M.D.
2000 Lewis L. Judd, M.D.	2019 Max Fink, M.D.
2001 Paul S. Appelbaum, M.D.	2020 Ned H. Kalin, M.D.
2002 Charles B. Nemeroff, M.D., Ph.D.	2021 Herbert Y. Meltzer, M.D.
2003 Dilip V. Jeste, M.D.	2022 Boris Birmaher, M.D.
2004 David H. Barlow, Ph.D.	2023 Altha J. Stewart, M.D.
2005 Herbert D. Kleber, M.D.	
2006 Daniel N. Stern, M.D.	

**Hartford
HealthCare**
Institute of Living

Nominations should be sent no later than June 7, 2024 to:
Javeed Sukhera, M.D., Ph.D., FRCPC
Chair/Chief of Psychiatry
Institute of Living/Hartford Hospital 200
Retreat Ave., Hartford, CT 06106
or e-mail to Faye.Jenkins@hhhealth.org

PSYCHIATRIC
NEWS

BRIEF

Enable

Psychiatric News Brief

With the American Psychiatric Association's new flash briefing, *Psychiatric News Brief*, you can now listen to synopses of curated articles from *Psychiatric News*. Simply enable this skill and you can listen anytime you choose throughout your day by just saying "Alexa, what's my flash briefing" or "Alexa, tell me what's new".



Flash briefing is a customizable Amazon skill that includes updates from your favorite content services. When you say, "Alexa, what's my flash briefing?" or "Alexa, what's the news," you'll hear updates from any organization that you have enabled.

Go to psychnews.psychiatryonline.org/alexa to sign up now!

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



www.appi.org
Email: appi@psych.org
Phone: 1-800-368-5777



For ADHD patients 6 years and older



A novel, nonstimulant ADHD treatment that works!^{1,2}

Qelbree[®] ONCE-DAILY
viloxazine
extended-release capsules
100 mg 150 mg 200 mg

Rethink ADHD Symptom Control



Patient portrayals.

*Branded ADHD products launched in last 6 years (as of September 2023).

INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

- *Suicidal thoughts and behaviors*: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
- *Heart rate, blood pressure increases*: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
- *Activation of mania or hypomania*: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression
- *Somnolence and fatigue*: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

ADVERSE REACTIONS

The most common adverse reactions ($\geq 5\%$ and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg.

Abbreviation: ADHD, attention-deficit/hyperactivity disorder.

REFERENCES: 1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc. 2. Food and Drug Administration. Novel drug approvals for 2021. May 13, 2022. Accessed January 7, 2023. <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>. 3. Data on file, Supernus Pharmaceuticals.

Please see the brief summary of full Prescribing Information including Boxed Warning, on adjacent pages, or visit QelbreeHCP.com.



Qelbree and Rethink ADHD Symptom Control are registered trademarks of Supernus Pharmaceuticals, Inc.
©2024 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2024-0019



Qelbree® (viloxazine extended-release capsules), for oral use
BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION

For full prescribing information, see package insert.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
In clinical studies, higher rates of suicidal thoughts and behavior were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.

INDICATIONS AND USAGE

Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

CONTRAINDICATIONS

Qelbree is contraindicated in patients receiving concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis.

Qelbree should not be taken when receiving concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range.

WARNINGS AND PRECAUTIONS

Suicidal Thoughts and Behaviors

Higher rates of suicidal thoughts and behaviors were reported in pediatric and adult patients with ADHD treated with Qelbree than in patients treated with placebo.

Among 1019 patients exposed to Qelbree 100 mg to 400 mg in short-term trials, a total of nine patients (0.9%) reported suicidal ideation (N=6), behavior (N=1) or both (N=2). Eight patients reported suicidal ideation or behavior on the Columbia Suicide Severity Rating Scale (C-SSRS), a validated scale that assesses suicide risk. An additional patient treated with Qelbree reported suicidal behavior during the clinical trials, but did not report it on the C-SSRS. Among 463 patients treated with placebo in these studies, two patients (0.4%) reported suicidal ideation on the C-SSRS. No patients treated with placebo reported suicidal behavior. No completed suicides occurred in these trials.

Among 189 adults treated with Qelbree, a total of three patients (1.6%) reported suicidal ideation on the C-SSRS, versus 0 of 183 adults treated with placebo. No adults treated with either Qelbree or placebo reported suicidal behavior on the C-SSRS in the study. No attempted or completed suicides occurred in the trial.

Patients treated with Qelbree had higher rates of insomnia and irritability. Although a causal link between the emergence of insomnia and irritability and the emergence of suicidal impulses has not been established, there is a concern that these and other symptoms such as depressed mood, anxiety, agitation, akathisia, mania, hypomania, panic attacks, impulsive behavior, and aggression may represent precursors to emerging suicidal ideation or behavior. Thus, patients being treated with Qelbree should be observed for the emergence of precursor symptoms.

Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes.

Consider changing the therapeutic regimen, including possibly discontinuing Qelbree, in patients who are experiencing emergent suicidal thoughts and behaviors or symptoms that might be precursors to emerging suicidal ideation or behavior, especially if these symptoms are severe or abrupt in onset, or were not part of the patient's presenting symptoms. Advise family members or caregivers of patients to monitor for the emergence of suicidal ideation or behavior, and to report such symptoms immediately to the healthcare provider.

Effects on Blood Pressure and Heart Rate

Qelbree can cause an increase in heart rate and diastolic blood pressure.

In a clinical study in patients 6 to 11 years of age, 34/154 (22%) of patients treated with Qelbree 100 mg daily had a ≥ 20 beat per minute (bpm) increase in heart rate at any time point in the clinical trial, compared to 15/159 (9%) of patients who received placebo. This finding was observed in 84/268 (31%) who received the 200 mg dose, compared to 39/262 (15%) of patients in the placebo group, and in 28/100 (28%) of patients who received the 400 mg dose, compared to 24/103 (23%) of patients who received placebo.

In a clinical study in patients 12 to 17 years of age, 22/99 (22%) of patients treated with Qelbree 200 mg daily had a ≥ 20 bpm increase in heart rate at any time point in the clinical trial, compared to 15/104 (14%) of patients who received placebo. This finding was observed in 69/205 (34%) who received the 400 mg dose, compared to 35/201 (17%) of patients in the placebo group.

In patients ages 12 to 17 years, 52/205 (25%) of patients treated with Qelbree 400 mg daily had a ≥ 15 mmHg increase in diastolic blood pressure at any time in the clinical trial, compared to 26/201 (13%) of patients in the placebo group.

In a clinical study in adult patients (18 to 60 years of age), 52/178 (29%) of patients treated daily with Qelbree (200 mg to 600 mg) had a ≥ 20 beat per minute (bpm) increase in heart rate at any time point in the clinical trial, compared to 23/181 (13%) of patients who received placebo. Of patients treated daily with Qelbree (200 to 600 mg), 23/178 (13%) had a ≥ 15 mmHg increase in diastolic blood

pressure at any time in the clinical trial, compared to 16/181 (9%) of patients in the placebo group.

Assess heart rate and blood pressure prior to initiating treatment with Qelbree, following increases in dosage, and periodically while on therapy.

Activation of Mania or Hypomania

Noradrenergic drugs, such as Qelbree, may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression.

Somnolence and Fatigue

Qelbree can cause somnolence and fatigue. In the short-term, placebo-controlled clinical trials in pediatric patients 6 to 17 years of age with ADHD, somnolence (including lethargy and sedation) was reported in 16% of Qelbree-treated patients compared to 4% of placebo-treated patients. Fatigue was reported in 6% of Qelbree-treated patients compared to 2% of placebo-treated patients.

In adults, somnolence was reported in 6% of Qelbree-treated patients versus 2% in placebo-treated patients. Fatigue was reported in 12% of Qelbree-treated patients versus 3% of placebo-treated patients.

Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by Qelbree.

ADVERSE REACTIONS

Clinical Trials Experience

The safety of Qelbree has been evaluated in 1118 patients 6 to 17 years of age with ADHD exposed to one or more doses in short-term (6 to 8 week), randomized, double-blind, placebo-controlled trials.

A total of 682 pediatric patients were treated for at least 6 months, and 347 pediatric patients for at least 12 months with Qelbree.

The safety of Qelbree has been evaluated in 189 adult patients (18 to 60 years of age) with ADHD exposed to one or more doses in a short-term (6 week), randomized, double-blind, placebo-controlled trial. A total of 277 adult patients with ADHD have been exposed to one or more doses of Qelbree.

Eighty-four adult patients were treated for at least 6 months, and 22 adult patients for at least 12 months.

The data described below reflect exposure to Qelbree in 826 patients (6 to 17 years) who participated in randomized, double-blind, placebo-controlled trials with doses ranging from 100 mg to 400 mg. The population (N=826) was 65% male, 35% female, 54% White, 41% Black, 4% multiracial, and 1% other races.

Adverse Reactions Leading to Discontinuation of Qelbree Treatment:

Approximately 3% (n=27) of the 826 patients receiving Qelbree in clinical studies discontinued treatment due to an adverse reaction. The adverse reactions most commonly associated with discontinuation of Qelbree were somnolence (n=5), nausea (n=3), headache (n=2), irritability (n=2), tachycardia (n=2), fatigue (n=2), and decreased appetite (n=2).

Most Common Adverse Reactions (occurring at $\geq 5\%$ and at least twice the placebo rate for any dose): somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability.

Tables 1 and 2 below lists adverse reactions that occurred in at least 2% of patients treated with Qelbree and more frequently in Qelbree-treated patients than in placebo-treated patients. Table 1 data represents pooled data from pediatric patients 6-17 years of age who were enrolled in randomized, placebo-controlled trials of Qelbree. Table 2 represents data from adults with ADHD who were enrolled in a flexible-dose, randomized, placebo-controlled trial of Qelbree at doses of 200mg to 600mg.

Table 1. Adverse Reactions Reported in $\geq 2\%$ of Pediatric Patients (6 to 17 Years of Age) Treated with Qelbree and at a Rate of Greater than Placebo-Treated Patients in Placebo-Controlled ADHD Studies

Body System Adverse Reaction	Placebo N=463 (%)	Qelbree			
		100mg N=154 (%)	200mg N=367 (%)	400mg N=305 (%)	All Qelbree N=836 (%)
Nervous system disorders					
Somnolence*	4	12	16	19	16
Headache*	7	10	11	11	11
Metabolic and nutritional disorders					
Decreased appetite	0.4	5	8	8	7
Infections and infestations					
Upper respiratory tract infections*	6	5	7	8	7
Body as a Whole - General disorders					
Fatigue	2	4	5	9	6
Pyrexia	0.2	3	2	1	2
Gastrointestinal system disorders					
Abdominal Pain*	4	3	6	7	5
Nausea	3	1	4	7	5
Vomiting	2	5	3	6	4

Table 1. Adverse Reactions Reported in ≥2% of Pediatric Patients (6 to 17 Years of Age) Treated with Qelbree and at a Rate of Greater than Placebo-Treated Patients in Qelbree-Controlled ADHD Studies (continued)

Body System Adverse Reaction	Placebo N=463 (%)	Qelbree			
		100mg N=154 (%)	200mg N=367 (%)	400mg N=305 (%)	All Qelbree N=836 (%)
Psychiatric disorders					
Insomnia*	1	2	5	5	4
Irritability	1	3	2	5	3

*The following items were combined:

Somnolence: somnolence, lethargy, sedation

Headache: headache, migraine, migraine with aura, tension headache

Upper respiratory tract infection: nasopharyngitis, pharyngitis, sinusitis, upper respiratory tract infection, viral sinusitis, viral upper respiratory tract infection

Abdominal pain: abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper

Insomnia: initial insomnia, insomnia, middle insomnia, poor quality sleep, sleep disorder, terminal insomnia

The data described below reflect exposure to Qelbree in 189 adults with ADHD who participated in the flexible-dose, randomized, double-blind, placebo-controlled trial with doses ranging from 200 mg to 600 mg. The population (N=189) was 56% male, 44% female, 81% White, 12% Black, 3% Asian, 3% other races and 1% multiracial.

Adverse Reactions Leading to Discontinuation of Qelbree Treatment:

Approximately 9% of the 189 patients receiving Qelbree in clinical studies discontinued treatment due to an adverse reaction. The adverse reactions most commonly associated with discontinuation of Qelbree were fatigue (n=4), insomnia (n=3), constipation (n=3), and headache (n=2).

Most Common Adverse Reactions (occurring at ≥5% and at least twice the placebo rate of Qelbree): insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

Listed here are adverse reactions that occurred in at least 2% of patients treated with Qelbree and more frequently in the Qelbree-treated patients than in the placebo-treated patients. Table 2 represents data from adults with ADHD who were enrolled in a flexible-dose, randomized, placebo-controlled trial of Qelbree at doses of 200 mg to 600 mg.

Table 2. Adverse Reactions Reported in ≥2% of Adults Treated with Qelbree and at a Rate Greater than Placebo-Treated Patients in a Flexible-Dose Placebo-Controlled ADHD Study

Body System Adverse Reaction	Placebo N=183 (%)	Qelbree (200 mg to 600 mg) N=189 (%)
Psychiatric disorders		
Insomnia*	7	23
Irritability	3	4
Nervous system disorders		
Headache*	7	17
Somnolence*	2	6
Dizziness	2	4
Gastrointestinal system disorders		
Nausea	3	12
Dry mouth	2	10
Constipation	1	6
Vomiting	1	4
Gastroesophageal reflux disease	1	2
Body as a Whole - General disorders		
Fatigue	3	12
Metabolic and nutritional disorders		
Decreased appetite	3	10
Cardiac disorders		
Tachycardia	1	4

*The following items were combined:

Somnolence: somnolence, lethargy, sedation

Headache: headache, migraine, migraine with aura, tension headache

Insomnia: initial insomnia, insomnia, middle insomnia, poor quality sleep, sleep disorder, terminal insomnia

DRUG INTERACTIONS

Drugs Having Clinically Important Interactions with Qelbree

Monoamine Oxidase Inhibitors (MAOI)

- Clinical Impact: Concomitant use of Qelbree with an MAOI may lead to a potentially life-threatening hypertensive crisis.
- Intervention: Concomitant use of Qelbree with an MAOI or within 2 weeks after discontinuing an MAOI is contraindicated.

Sensitive CYP1A2 Substrates or CYP1A2 Substrates with a Narrow Therapeutic Range

- Clinical Impact: Viloxazine is a strong CYP1A2 inhibitor. Concomitant use of viloxazine significantly increases the total exposure, but not peak exposure, of

sensitive CYP1A2 substrates, which may increase the risk of adverse reactions associated with these CYP1A2 substrates.

- Intervention: Coadministration with Qelbree is contraindicated.

Moderate Sensitive CYP1A2 Substrate

- Clinical Impact: Viloxazine is a strong CYP1A2 inhibitor. Concomitant use of viloxazine significantly increases the total, but not peak, exposure of sensitive CYP1A2 substrates, which may increase the risk of adverse reactions associated with these CYP1A2 substrates.
- Intervention: Not recommended for coadministration with Qelbree. Dose reduction may be warranted if coadministered.

CYP2D6 Substrates

- Clinical Impact: Viloxazine is a weak inhibitor of CYP2D6, and increases the exposure of CYP2D6 substrates when coadministered.
- Intervention: Monitor patients for adverse reactions and adjust dosages of CYP2D6 substrates, as clinically indicated.

CYP3A4 Substrates

- Clinical Impact: Viloxazine is a weak inhibitor of CYP3A4 which increases the exposure of CYP3A4 substrates when coadministered.
- Intervention: Monitor patients for adverse reactions and adjust dosages of CYP3A4 substrates, as clinically indicated.

USE IN SPECIFIC POPULATIONS

Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388, or visiting online at www.womensmentalhealth.org/peg.

Risk Summary

Based on findings from animal reproduction studies, viloxazine may cause maternal harm when used during pregnancy. Discontinue Qelbree when pregnancy is recognized unless the benefits of therapy outweigh the potential risk to the mother. Available data from case series with viloxazine use in pregnant women are insufficient to determine a drug-associated risk of major birth defects, miscarriage or adverse maternal outcomes.

In animal reproduction studies, oral administration of viloxazine during the period of organogenesis caused fetal toxicities and delayed fetal development in the rat and maternal toxicities in the rabbit at doses approximately equal to the maximum recommended human dose (MRHD) of 600mg in adults, based on mg/m². Oral administration of viloxazine to pregnant rats and mice during pregnancy and lactation caused maternal toxicities and deaths and fetal toxicities at doses equal to or less than the MRHD of 600mg in adults, based on mg/m², respectively.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcome. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Lactation

Risk Summary

There are no data on the presence of viloxazine in human milk, the effects on the breastfed infant, or the effects on milk production. Viloxazine is likely present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Qelbree and any potential adverse effects on the breastfed child from Qelbree or from the underlying maternal condition.

Geriatric Use

Clinical trials of Qelbree in the treatment of ADHD did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients.

Renal Impairment

Dosage reduction is recommended in patients with severe (eGFR of < 30 mL/min/1.73m² [MDRD]) renal impairment.

No dosage adjustment of Qelbree is recommended in patients with mild to moderate (eGFR of 30 to 89 mL/min/1.73m² [MDRD]) renal impairment.

The exposure of viloxazine increases in patients with renal impairment.

OVERDOSAGE

Human Experience

The pre-market clinical trials with Qelbree do not provide information regarding symptoms of overdose.

Literature reports from post marketing experience with immediate-release viloxazine include cases of overdose from 1000 mg to 6500 mg (1.7 to 10.8 times the maximum recommended daily dose). The most reported symptom was drowsiness. Impaired consciousness, diminished reflexes, and increased heart rate have also been reported.

Treatment and Management

There is no specific antidote for Qelbree overdose. Administer symptomatic and supportive treatment as appropriate. In case of overdose, consult a Certified Poison Control Center (1-800-222-1222 or www.poison.org).



Join a psychiatry team that supports each other on and off the job

Enhance your career in mental health by joining our team of over 100 dedicated psychiatrists. Elevate your lifestyle in beautiful B.C. with opportunities in both urban and rural locations.



Learn more at vch.ca/careers








Providence Health Care

Vancouver Coastal Health

APA Publishing **Audio Books** Listen anytime, anywhere



Purchase and listen at appi.org



AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



www.appi.org
Email: appi@psych.org
Toll-Free: 1-800-368-5777

Also available at: Google Podcasts, Apple Podcasts, Spotify, Stitcher, and YouTube